Great Bay Bio Forged Strategic Alliance with Cheerland Life Science

2022-01-26

[HONG KONG, January 28, 2022] Great Bay Bio Group Limited (hereinafter referred to as“GBB”), an AI-enabled biotechnology company, announced today that it has formeda strategic alliance with Cheerland Life Science (hereinafter referred to as“Cheerland”), jointly promoting the development of an AI driven CDMO in the GreaterBay Area and creating more value for the global biopharmaceutical ecosystem.



GBB is ahigh-tech enterprise dedicated to applying artificial intelligence and othercutting-edge technologies to the development of biopharmaceuticals. As the globalpioneer of "AI + CMC" platform, GBB aims to solve the pain points ofbiopharmaceutical CMC development by using AI technology. Cheerland is a CDMO service enterprise with comprehensive clinical and commercial biopharmaceuticalservice offerings, world-class production equipment and first-class operationand management team. By combining GBB’s AI-enabled CDO development platform andCheerland’s commercial scale CDMO capability, this strategic alliance would jointlypromote the development of AI-enabled commercial scale CDMO, with an initialfocus to develop the biopharmaceutical industry in the Greater Bay Area. Inaddition, GBB and Cheerland are expected to provide better services to moreinternational and domestic prospective clients by leveraging the uniquegeographical and policy advantages of the Greater Bay Area.


GBB has threecommercial AI-enabled bioprocessing development platforms, including AI-enabledcell line development platform Klone4.0™, AI-enabled cell line stabilityprediction platform AlfaStaX®and AI-enabled culture media development platformAlfaMedX®. AI technology holds great promise to reduce repetitive labor, reducescreening times and greatly improve the success rate and efficiency of key CMCsteps, such as cell line development and media formulation development.


Dr. Chen Liang,founder and CEO of GBB, said, “We are glad that we have reached the strategicalliance with Cheerland. Cheerland has one of the world’s leading cGMP CDMOproduction facilities, with a total production capacity of 1.31 million liters.GBB owns strong innovation ability in the biopharmaceutical CDO phase, which reinforcesCheerland’s downstream value proposition. Through this strategic alliance, GBBcan strengthen our ability to provide customers with large-volume CMOcapabilities. Moreover, this alliance can promote the steady development ofGBB’s culture media business.”


Michael Garvey,president and executive director of Cheerland, commented, “With world-classmanagement team and top-level equipment, Cheerland is committed to becoming theworld's first biological drug development and manufacturing CDMO, servingglobal pharmaceutical enterprises, greatly reducing the cost of biologicaldrugs and producing reassuring drugs that people can afford throughlarge-scale, intelligent and commercial production. The strength of Cheerlandis commercial production, the establishment of strategic alliance with GBB hasvery significant complementary advantages. Through this strategic alliance, wewill bring more comprehensive solutions to customers, greatly shorten the cyclefrom clinical research to commercial production of biological drugs, andbenefit tens of millions of patients. In addition, we are all located in theGreater Bay Area. We will work together to promote the vigorous development ofbiomedical industry in the Greater Bay Area and contribute together to build a"Healthy China".”


About Cheerland

Cheerland closely follows the national industrial orientation and focuses on cutting-edge biotechnology. In 2021, Cheerland was ed as the "National BrandProject Of Xinhua News Agency" and is committed to becoming a national biotechnology leader. Dr. James Watson, the Nobel laureate and "father ofDNA", is the general scientific consultant of Cheerland. Cheerland focuseson investment introduction and independent R&D, creating a precisionmedical industry ecology integrating biomedical development and manufacturing, scientific and technological medical services, genetic testing and innovativedrugs, and constantly pursuing the mission of "Healthy Cheerland, Healthy China".

Message